▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1808 by analyst upside · 2026-09-26
ANIP
ANI Pharmaceuticals, Inc.
Healthcare · Market Cap $2B · P/E 16.2x
ANALYST PRICE TARGET
+42.9%
implied upside to consensus target
Current Price $74.0
Consensus Target $105.78
Bull Target $121.0
Bear Target $85.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
4
Hold
2
Sell
0
52-Week Low $69.58
52-Week High $97.0
YTD Return -5.6%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 16.2x
Forward P/E 7.1x
EPS (TTM) $4.57
PEG Ratio 1.84
Dividend Yield N/A
Revenue (TTM) $978M
Profit Margin 11.1%
52-WEEK RANGE
52-Week Low $69.58
52-Week High $97.0
Current Price $74.0
Bear Target $85.0
Bull Target $121.0
● Now $74.0 ● Target $105.78
TRADING DATA
Avg Volume 370K
YTD Return -5.6%
Analyst Count 9
Consensus Buy
Upside to Target +42.9%
Last Updated 2026-09-26

ANALYST SUMMARY

ANI Pharmaceuticals, Inc. (ANIP) is currently trading at $74.0 with a Wall Street consensus price target of $105.78, implying potential upside of 42.9% over the next 12 months. 9 analysts currently cover ANIP, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $121.0, while the most cautious has a target of $85.0.

ANIP operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 5.6% year-to-date and is currently trading near the lower end of its 52-week range of $69.58 – $97.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ANIP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer ● Initiated
Perform 2026-09-23 14% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-08-10 62% win rate (8 calls)
Canaccord Genuity - Reiterated
Hold → Hold 2026-08-10 Building track record
Canaccord Genuity ● Initiated
Hold 2026-07-17 Building track record
Guggenheim reit
Buy → Buy 2026-07-10 62% win rate (8 calls)
Guggenheim - Reiterated
Buy → Buy 2026-01-16 62% win rate (8 calls)
Barclays ● Initiated
Overweight 2025-12-09 Building track record
Guggenheim - Reiterated
Buy → Buy 2025-11-10 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
52
out of 100
Coverage depth
18/30
Consensus clarity
20/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →